checkAd

     179  0 Kommentare Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program - Seite 4

    About Novartis
    Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
    For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
    For questions about the site or required registration, please contact media.relations@novartis.com

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Novartis AG!
    Long
    88,98€
    Basispreis
    0,67
    Ask
    × 14,78
    Hebel
    Short
    99,94€
    Basispreis
    0,71
    Ask
    × 13,97
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    # # #

    Novartis Media Relations
    E-mail: media.relations@novartis.com

    Anja von Treskow
    Novartis External Communications
    +41 79 392 8697 (mobile)
    anja.von_treskow@novartis.com

     

    Eric Althoff
    Novartis US External Communications
    +1 646 438 4335
    eric.althoff@novartis.com
    Farah Bulsara Speer
    SVP, Corporate Communications, Novartis Gene Therapies
    +1 312 543 2881 (mobile)
    farah.speer@novartis.com

     

     

    Novartis Investor Relations
    Central investor relations line: +41 61 324 7944
    E-mail: investor.relations@novartis.com

    Central   North America  
    Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
    Thomas Hungerbuehler        
    Isabella Zinck
    +41 61 324 8425
    +41 61 324 7188
       
           
           

    Seite 4 von 4


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program - Seite 4 Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September 23, 2020 – Novartis Gene Therapies recently …

    Schreibe Deinen Kommentar

    Disclaimer